Vivimed To Pay $1.9M To End Losartan Economic Loss Claims
By George Woolston · December 4, 2025, 3:17 PM EST
Vivimed has agreed to pay $1.9 million to settle economic loss claims from a class of consumers and insurers related to its losartan product in sprawling multidistrict litigation over contaminated blood...
To view the full article, register now.